Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers Eight U.S. Locations, December 2020 March 2021

Mark G. Thompson; Jefferey L. Burgess; Allison L. Naleway; Harmony L. Tyner; Sarang K. Yoon; Jennifer Meece; Lauren E.W. Olsho; Alberto J. Caban-Martinez; Ashley Fowlkes; Karen Lutrick; Jennifer L. Kuntz; Kayan Dunnigan; Marilyn J. Odean; Kurt T. Hegmann; Elisha Stefanski; Laura J. Edwards; Natasha Schaefer-Solle; Lauren Grant; Katherine Ellingson; Holly C. Groom; Tnelda Zunie; Matthew S. Thiese; Lynn Ivacic; Meredith G. Wesley; Julie Mayo Lamberte; Xiaoxiao Sun; Michael E. Smith; Andrew L. Phillips; Kimberly D. Groover; Young M. Yoo; Joe Gerald; Rachel T. Brown; Meghan K. Herring; Gregory Joseph; Shawn Beitel; Tyler C. Morrill; Josephine Mak; Patrick Rivers; Katherine M. Harris; Danielle R. Hunt; Melissa L. Arvay; Preeta Kutty; Alicia M. Fry; Manjusha Gaglani

doi:10.15585/MMWR.MM7013E3

Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers Eight U.S. Locations, December 2020 March 2021

Mark G. Thompson, Jefferey L. Burgess, Allison L. Naleway, Harmony L. Tyner, Sarang K. Yoon, Jennifer Meece, Lauren E.W. Olsho, Alberto J. Caban-Martinez, Ashley Fowlkes, Karen Lutrick, Jennifer L. Kuntz, Kayan Dunnigan, Marilyn J. Odean, Kurt T. Hegmann, Elisha Stefanski, Laura J. Edwards, Natasha Schaefer-Solle, Lauren Grant, Katherine Ellingson, Holly C. GroomTnelda Zunie, Matthew S. Thiese, Lynn Ivacic, Meredith G. Wesley, Julie Mayo Lamberte, Xiaoxiao Sun, Michael E. Smith, Andrew L. Phillips, Kimberly D. Groover, Young M. Yoo, Joe Gerald, Rachel T. Brown, Meghan K. Herring, Gregory Joseph, Shawn Beitel, Tyler C. Morrill, Josephine Mak, Patrick Rivers, Katherine M. Harris, Danielle R. Hunt, Melissa L. Arvay, Preeta Kutty, Alicia M. Fry, Manjusha Gaglani

Research output: Contribution to journal › Article › peer-review

558 Scopus citations

Abstract

What is already known about this topic? Messenger RNA (mRNA) COVID-19 vaccines have been shown to be effective in preventing symptomatic SARS-CoV-2 infection in randomized placebo-controlled Phase III trials. What is added by this report? Prospective cohorts of 3,950 health care personnel, first responders, and other essential and frontline workers completed weekly SARS-CoV-2 testing for 13 consecutive weeks. Under real-world conditions, mRNA vaccine effectiveness of full immunization (≥14 days after second dose) was 90% against SARS-CoV-2 infections regardless of symptom status; vaccine effectiveness of partial immunization (≥14 days after first dose but before second dose) was 80%. What are the implications for public health practice? Authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection in real-world conditions. COVID-19 vaccination is recommended for all eligible persons.

Original language	English (US)
Pages (from-to)	495-500
Number of pages	6
Journal	Morbidity and Mortality Weekly Report
Volume	70
Issue number	13
DOIs	https://doi.org/10.15585/MMWR.MM7013E3
State	Published - 2021

ASJC Scopus subject areas

Epidemiology
Health(social science)
Health, Toxicology and Mutagenesis
Health Information Management

Access to Document

10.15585/MMWR.MM7013E3

Fingerprint

Dive into the research topics of 'Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers Eight U.S. Locations, December 2020 March 2021'. Together they form a unique fingerprint.

Cite this

Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., Kuntz, J. L., Dunnigan, K., Odean, M. J., Hegmann, K. T., Stefanski, E., Edwards, L. J., Schaefer-Solle, N., Grant, L., Ellingson, K., ... Gaglani, M. (2021). Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers Eight U.S. Locations, December 2020 March 2021. Morbidity and Mortality Weekly Report, 70(13), 495-500. https://doi.org/10.15585/MMWR.MM7013E3

Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers Eight U.S. Locations, December 2020 March 2021. / Thompson, Mark G.; Burgess, Jefferey L.; Naleway, Allison L. et al.
In: Morbidity and Mortality Weekly Report, Vol. 70, No. 13, 2021, p. 495-500.

Research output: Contribution to journal › Article › peer-review

Thompson, MG, Burgess, JL, Naleway, AL, Tyner, HL, Yoon, SK, Meece, J, Olsho, LEW, Caban-Martinez, AJ, Fowlkes, A, Lutrick, K, Kuntz, JL, Dunnigan, K, Odean, MJ, Hegmann, KT, Stefanski, E, Edwards, LJ, Schaefer-Solle, N, Grant, L, Ellingson, K, Groom, HC, Zunie, T, Thiese, MS, Ivacic, L, Wesley, MG, Lamberte, JM, Sun, X, Smith, ME, Phillips, AL, Groover, KD, Yoo, YM, Gerald, J, Brown, RT, Herring, MK, Joseph, G, Beitel, S, Morrill, TC, Mak, J, Rivers, P, Harris, KM, Hunt, DR, Arvay, ML, Kutty, P, Fry, AM & Gaglani, M 2021, 'Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers Eight U.S. Locations, December 2020 March 2021', Morbidity and Mortality Weekly Report, vol. 70, no. 13, pp. 495-500. https://doi.org/10.15585/MMWR.MM7013E3

Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers Eight U.S. Locations, December 2020 March 2021. Morbidity and Mortality Weekly Report. 2021;70(13):495-500. doi: 10.15585/MMWR.MM7013E3

Thompson, Mark G. ; Burgess, Jefferey L. ; Naleway, Allison L. et al. / Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers Eight U.S. Locations, December 2020 March 2021. In: Morbidity and Mortality Weekly Report. 2021 ; Vol. 70, No. 13. pp. 495-500.

@article{355862f51848409f8136aff24ddb68e5,

title = "Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers Eight U.S. Locations, December 2020 March 2021",

abstract = "What is already known about this topic? Messenger RNA (mRNA) COVID-19 vaccines have been shown to be effective in preventing symptomatic SARS-CoV-2 infection in randomized placebo-controlled Phase III trials. What is added by this report? Prospective cohorts of 3,950 health care personnel, first responders, and other essential and frontline workers completed weekly SARS-CoV-2 testing for 13 consecutive weeks. Under real-world conditions, mRNA vaccine effectiveness of full immunization (≥14 days after second dose) was 90\% against SARS-CoV-2 infections regardless of symptom status; vaccine effectiveness of partial immunization (≥14 days after first dose but before second dose) was 80\%. What are the implications for public health practice? Authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection in real-world conditions. COVID-19 vaccination is recommended for all eligible persons.",

author = "Thompson, \{Mark G.\} and Burgess, \{Jefferey L.\} and Naleway, \{Allison L.\} and Tyner, \{Harmony L.\} and Yoon, \{Sarang K.\} and Jennifer Meece and Olsho, \{Lauren E.W.\} and Caban-Martinez, \{Alberto J.\} and Ashley Fowlkes and Karen Lutrick and Kuntz, \{Jennifer L.\} and Kayan Dunnigan and Odean, \{Marilyn J.\} and Hegmann, \{Kurt T.\} and Elisha Stefanski and Edwards, \{Laura J.\} and Natasha Schaefer-Solle and Lauren Grant and Katherine Ellingson and Groom, \{Holly C.\} and Tnelda Zunie and Thiese, \{Matthew S.\} and Lynn Ivacic and Wesley, \{Meredith G.\} and Lamberte, \{Julie Mayo\} and Xiaoxiao Sun and Smith, \{Michael E.\} and Phillips, \{Andrew L.\} and Groover, \{Kimberly D.\} and Yoo, \{Young M.\} and Joe Gerald and Brown, \{Rachel T.\} and Herring, \{Meghan K.\} and Gregory Joseph and Shawn Beitel and Morrill, \{Tyler C.\} and Josephine Mak and Patrick Rivers and Harris, \{Katherine M.\} and Hunt, \{Danielle R.\} and Arvay, \{Melissa L.\} and Preeta Kutty and Fry, \{Alicia M.\} and Manjusha Gaglani",

year = "2021",

doi = "10.15585/MMWR.MM7013E3",

language = "English (US)",

volume = "70",

pages = "495--500",

journal = "Morbidity and Mortality Weekly Report",

issn = "0149-2195",

publisher = "Department of Health and Human Services",

number = "13",

}

TY - JOUR

T1 - Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers Eight U.S. Locations, December 2020 March 2021

AU - Thompson, Mark G.

AU - Burgess, Jefferey L.

AU - Naleway, Allison L.

AU - Tyner, Harmony L.

AU - Yoon, Sarang K.

AU - Meece, Jennifer

AU - Olsho, Lauren E.W.

AU - Caban-Martinez, Alberto J.

AU - Fowlkes, Ashley

AU - Lutrick, Karen

AU - Kuntz, Jennifer L.

AU - Dunnigan, Kayan

AU - Odean, Marilyn J.

AU - Hegmann, Kurt T.

AU - Stefanski, Elisha

AU - Edwards, Laura J.

AU - Schaefer-Solle, Natasha

AU - Grant, Lauren

AU - Ellingson, Katherine

AU - Groom, Holly C.

AU - Zunie, Tnelda

AU - Thiese, Matthew S.

AU - Ivacic, Lynn

AU - Wesley, Meredith G.

AU - Lamberte, Julie Mayo

AU - Sun, Xiaoxiao

AU - Smith, Michael E.

AU - Phillips, Andrew L.

AU - Groover, Kimberly D.

AU - Yoo, Young M.

AU - Gerald, Joe

AU - Brown, Rachel T.

AU - Herring, Meghan K.

AU - Joseph, Gregory

AU - Beitel, Shawn

AU - Morrill, Tyler C.

AU - Mak, Josephine

AU - Rivers, Patrick

AU - Harris, Katherine M.

AU - Hunt, Danielle R.

AU - Arvay, Melissa L.

AU - Kutty, Preeta

AU - Fry, Alicia M.

AU - Gaglani, Manjusha

PY - 2021

Y1 - 2021

N2 - What is already known about this topic? Messenger RNA (mRNA) COVID-19 vaccines have been shown to be effective in preventing symptomatic SARS-CoV-2 infection in randomized placebo-controlled Phase III trials. What is added by this report? Prospective cohorts of 3,950 health care personnel, first responders, and other essential and frontline workers completed weekly SARS-CoV-2 testing for 13 consecutive weeks. Under real-world conditions, mRNA vaccine effectiveness of full immunization (≥14 days after second dose) was 90% against SARS-CoV-2 infections regardless of symptom status; vaccine effectiveness of partial immunization (≥14 days after first dose but before second dose) was 80%. What are the implications for public health practice? Authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection in real-world conditions. COVID-19 vaccination is recommended for all eligible persons.

AB - What is already known about this topic? Messenger RNA (mRNA) COVID-19 vaccines have been shown to be effective in preventing symptomatic SARS-CoV-2 infection in randomized placebo-controlled Phase III trials. What is added by this report? Prospective cohorts of 3,950 health care personnel, first responders, and other essential and frontline workers completed weekly SARS-CoV-2 testing for 13 consecutive weeks. Under real-world conditions, mRNA vaccine effectiveness of full immunization (≥14 days after second dose) was 90% against SARS-CoV-2 infections regardless of symptom status; vaccine effectiveness of partial immunization (≥14 days after first dose but before second dose) was 80%. What are the implications for public health practice? Authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection in real-world conditions. COVID-19 vaccination is recommended for all eligible persons.

UR - https://www.scopus.com/pages/publications/85103861981

UR - https://www.scopus.com/inward/citedby.url?scp=85103861981&partnerID=8YFLogxK

U2 - 10.15585/MMWR.MM7013E3

DO - 10.15585/MMWR.MM7013E3

M3 - Article

C2 - 33793460

AN - SCOPUS:85103861981

SN - 0149-2195

VL - 70

SP - 495

EP - 500

JO - Morbidity and Mortality Weekly Report

JF - Morbidity and Mortality Weekly Report

IS - 13

ER -

Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers Eight U.S. Locations, December 2020 March 2021

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this